Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Complement C5 mediates experimental tubulointerstitial fibrosis.

Peter Boor1, Andrzej Konieczny, Luigi Villa

  • 1Division of Nephrology, Rheinische-Westfälische Technische Hochschule, University of Aachen, Aachen, Germany.

Journal of the American Society of Nephrology : JASN
|March 29, 2007
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Iptacopan in IgA Nephropathy - Final 24-Month Data.

The New England journal of medicine·2026
Same author

The Incidence and Correlation of Renal Pathologies Based on 14-Year Kidney Biopsy Material: A Retrospective Single-Centre Study in Poland.

Journal of clinical medicine·2026
Same author

Clinical Model Predicting Presence of Diabetic Nephropathy in Renal Biopsy Performed on Patients with Diabetes.

Journal of clinical medicine·2026
Same author

Dipsticks and point-of-care Microscopy in Urinary Tract Infections in primary care: Results of the MicUTI pilot cluster randomised controlled trial.

PloS one·2025
Same author

Prognostic Factors of Proteinuria Remission in Primary Membranous Nephropathy.

Journal of clinical medicine·2025
Same author

Affinity on Demand: A One-Pot Method for Synthesis and Sample Enrichment Using TentaGel-Functionalized Resins.

ACS omega·2025

Complement C5 (C5) and its fragment C5a promote kidney fibrosis. Blocking C5a signaling reduced fibrosis markers in mouse models, identifying C5 as a potential therapeutic target for renal disease.

Area of Science:

  • Nephrology
  • Immunology
  • Molecular Biology

Background:

  • Renal fibrosis is a common outcome in progressive kidney diseases.
  • Complement C5 (C5) is a known risk factor for liver fibrosis.
  • The role of C5 in renal fibrosis remains largely unexplored.

Purpose of the Study:

  • To investigate the role of C5 in the development of renal tubulointerstitial fibrosis.
  • To evaluate the therapeutic potential of targeting C5a signaling in renal fibrosis.

Main Methods:

  • Induction of renal fibrosis in wild-type and C5-deficient mice using unilateral ureteral obstruction (UUO).
  • Administration of a C5a receptor antagonist (C5aRA) in UUO mouse models.
  • Assessment of renal fibrosis markers, gene expression (PDGF, TGF-beta1), and C5a receptor (C5aR) expression.

Related Experiment Videos

  • In vitro studies using cultured murine cortical tubular cells.

    • Main Results:

    • C5-deficient mice exhibited significantly reduced renal fibrosis markers and inflammatory cell infiltration post-UUO.
    • Fibronectin mRNA and protein expression were decreased in C5-deficient mice.
    • Treatment with C5aRA significantly reduced fibrosis markers and PDGF-B mRNA expression in wild-type mice.
    • C5a stimulated TGF-beta1 production in cultured tubular cells, an effect inhibited by C5aRA.

    Conclusions:

    • C5, particularly C5a, acts as a novel profibrotic factor in the kidney.
    • Targeting C5a signaling presents a potential therapeutic strategy for renal fibrosis.
    • Genetic deficiency or pharmacological inhibition of C5/C5a reduces renal tubulointerstitial fibrosis.